Retinal Vein Occlusion Market to Grow Positively at a Paltry CAGR During the Study Period, DelveInsight | AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences Inc,

DelveInsight's "Retinal Vein Occlusion - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Retinal Vein Occlusion market share of the individual therapies, current and forecasted Retinal Vein Occlusion market size from 2020 to 2034 segmented by seven major markets. The report also offers current Retinal Vein Occlusion therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Retinal Vein Occlusion market.
Download our latest retinal vein occlusion market report @ https://www.delveinsight.com/report-store/retinal-vein-occlusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the retinal vein occlusion market report:
In 2022, the total market size for Retinal Vein Occlusion (RVO) across the 7MM was approximately USD 2,297.5 million and is expected to grow during the forecast period from 2023 to 2034.
In the US, the RVO market was valued at about USD 1,611.9 million in 2022, with growth anticipated due to heightened disease awareness and the introduction of new therapies.
The EU4 countries and the UK collectively accounted for approximately USD 453.9 million in market revenue in 2022, representing around 20% of the total RVO market across the 7MM.
Japan had the second-largest market for RVO among the 7MM, with revenues of approximately USD 231.7 million in 2022. This market is also expected to experience significant growth by 2034.
The rising prevalence of RVO is attributed to an aging population and increasing awareness of eye disorders. Advances in diagnosis and the growing incidence of diabetes and other lifestyle-related conditions contribute to the higher prevalence and impact of RVO.
Current treatments for RVO include anti-VEGF therapies, corticosteroids, laser therapy, and various off-label treatments. Intravitreal steroids and anti-VEGFs are used for macular perfusion and ischemia, while laser therapy addresses neovascularization and challenging cases.
FDA-approved medications for RVO include LUCENTIS (ranibizumab, Roche/Novartis), EYLEA (aflibercept, Regeneron Pharmaceuticals/Bayer/Santen), OZURDEX (dexamethasone intravitreal implant, AbbVie), and the recently approved VABYSMO (faricimab, Roche/Chugai Pharmaceutical). Additionally, AVASTIN (bevacizumab) and intravitreal triamcinolone are used off-label to help maintain or improve vision.

Retinal Vein Occlusion Overview
Retinal Vein Occlusion (RVO) is the second most common sight-threatening retinal vascular disorder after diabetic retinopathy. It is characterized by the blockage of small veins that carry blood away from the retina. This condition is often triggered by atherosclerosis and the formation of blood clots, leading to sudden changes in vision. The extent of vision impairment depends on the severity and location of the blockage. Increased pressure in the capillaries due to the blockage can cause hemorrhage and fluid leakage, potentially resulting in macular edema near the macula.

Risk factors for RVO include systemic conditions such as hypertension, arteriosclerosis, diabetes mellitus, hyperlipidemia, stroke, blood hyperviscosity, and thrombophilia. Individuals with end-organ damage face a significantly higher risk. Ophthalmic risk factors include ocular hypertension, glaucoma, higher ocular perfusion pressure, and changes in the retinal arteries.

RVO is classified into two main types based on the location of the blockage: Central Retinal Vein Occlusion (CRVO) and Branch Retinal Vein Occlusion (BRVO). CRVO is further divided into nonischemic and ischemic types based on fluorescein angiography results. BRVO is categorized into Major Branch RVO (when a major branch retinal vein is occluded, typically near the optic disc) and Macular Branch RVO (when a macular venule is occluded).

RVO is particularly prevalent among elderly patients, with a higher incidence in individuals over 65 years of age. Age and systemic vascular disorders are key risk factors, with age being a major determinant of disease progression. As the geriatric population grows, the prevalence of RVO is expected to rise.

One of the major complications of RVO is macular edema, which can lead to significant visual loss. Various treatments are available to address macular edema and manage intraocular neovascularization.
Know more in detail about retinal vein occlusion @ https://www.delveinsight.com/report-store/retinal-vein-occlusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Retinal Vein Occlusion Epidemiology Insight
In the 7MM, there were approximately 2,718,067 prevalent cases of Retinal Vein Occlusion (RVO) in 2022. The US accounted for about 57% of these cases, while the EU4 and the UK collectively represented nearly 30%, and Japan contributed approximately 13%. This prevalence is expected to rise by 2034.
In the US, which had nearly 61% of the total diagnosed RVO cases in the 7MM, there were approximately 935,343 cases in 2022. This number is anticipated to grow throughout the study period from 2020 to 2034.
According to DelveInsight, the EU4 and the UK had around 408,086 diagnosed RVO cases in 2022, with expected changes during the forecast period (2020-2034). Among these countries, Germany reported the highest number of diagnosed cases, accounting for approximately 28% of the total, followed by Italy and France, with Spain having the fewest cases.
DelveInsight's epidemiology model estimates that in the US, Retinal Vein Occlusion affects a slightly higher percentage of females than males. In 2022, about 48% of the diagnosed cases were male, while 52% were female.

Retinal Vein Occlusion Market Outlook
Retinal Vein Occlusion (RVO) is a major cause of vision loss globally, ranking second only to diabetic retinopathy among retinal vascular disorders. It involves the blockage of small veins in the retina, often due to atherosclerosis, leading to sudden vision changes. While RVO cannot be reversed, treatment aims to stabilize vision by addressing leaking blood vessels and related complications.

Currently, there are no treatments available to unblock retinal veins directly. However, managing associated health issues and using specific therapies can help. About one-third of patients may experience some vision improvement, another third may see no change, and the remaining third may show gradual improvement, which could take over a year to fully assess. Complications such as fluid accumulation or new blood vessel formation in the retina can occur.

FDA-approved treatments for RVO include:
- LUCENTIS (ranibizumab): A VEGF inhibitor developed by Roche and marketed by Novartis, approved in 2010 for macular edema from RVO. It prevents the growth of abnormal blood vessels but may have risks like retinal detachment and serious eye infections.
- EYLEA (aflibercept): Approved in 2014 by Regeneron, this anti-VEGF injection blocks both VEGF-A and PLGF, addressing new blood vessel growth and vascular permeability.
- VABYSMO (faricimab): Recently approved in 2023, this drug uses CrossMab technology to inhibit both VEGF and angiopoietin pathways, promising reduced treatment burden and improved vision outcomes.
- OZURDEX (dexamethasone intravitreal implant): Approved in 2009, this corticosteroid is used for chronic edema cases that do not respond well to anti-VEGF injections. It holds a significant position in the market due to its patent exclusivity and lack of direct competitors.

Off-label treatments like AVASTIN (bevacizumab) and intravitreal triamcinolone are also used for managing RVO. Despite these advances, many patients continue to suffer vision loss due to RVO-related photoreceptor cell death. Future research may focus on neuroprotective and photoreceptor regeneration therapies to improve outcomes.

Emerging therapies in development include Kodiak Sciences' tarcocimab tedromer (KSI-301), Outlook Therapeutics' LYTENAVA (ONS-5010), Taiwan Liposome Company's TLC399 (ProDex), and Alcon's AR-1105 (dexamethasone implant), which could further enhance treatment options for RVO.
Discover how the retinal vein occlusion market is growing in the upcoming years @ https://www.delveinsight.com/sample-request/retinal-vein-occlusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Promising Therapies in the Retinal Vein Occlusion Pipeline
Lucentis (ranibizumab)
Ozurdex (dexamethasone)
KSI-301
Vabysmo (faricimab)
TLC399 (ProDex)
And others
Discover more about Retinal Vein Occlusion therapies in the pipeline @ https://www.delveinsight.com/sample-request/retinal-vein-occlusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Retinal Vein Occlusion Market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences Inc, Chugai Pharmaceuticals, and others.
To understand key companies related to the Retinal Vein Occlusion Market, get a snapshot of the Retinal Vein Occlusion Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/retinal-vein-occlusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Retinal Vein Occlusion Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Retinal Vein Occlusion Companies: AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences Inc, Chugai Pharmaceuticals, and others
Key Retinal Vein Occlusion Pipeline Therapies: Lucentis (ranibizumab), Ozurdex (dexamethasone), KSI-301, Vabysmo (faricimab), TLC399 (ProDex), and others
Therapeutic Assessment: Retinal Vein Occlusion current marketed and emerging therapies
Retinal Vein Occlusion Market Dynamics: Retinal Vein Occlusion market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Retinal Vein Occlusion Market Access and Reimbursement
Table of Contents
1. Retinal Vein Occlusion Market Key Insights
2. Retinal Vein Occlusion Market Report Introduction
3. Retinal Vein Occlusion Market Overview at a Glance
4. Retinal Vein Occlusion Market Executive Summary
5. Disease Background and Overview
6. Retinal Vein Occlusion Treatment and Management
7. Retinal Vein Occlusion Epidemiology and Patient Population
8. Patient Journey
9. Retinal Vein Occlusion Emerging Drugs
10. 7MM Retinal Vein Occlusion Market Analysis
11. Retinal Vein Occlusion Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Retinal Vein Occlusion Market Drivers
15. Retinal Vein Occlusion Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.